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ABSTRACT
Background: The Keele STarT MSK Tool is a 10-item questionnaire developed to classify patients suffering from one of the five
most common types of musculoskeletal pain into three sub-groups according to their risk of chronic pain (i.e. low risk, medium
risk and high risk). Objectives: The objective of the present study was to translate the Keele STarT MSK Tool into French and
to evaluate its main psychometric properties. Methods: The translation and intercultural adaptation of the questionnaire were
carried out using a 6-step process. The following psychometric properties were investigated: floor and ceiling effects, construct
validity, internal consistency and test-retest reliability including Standard Error of Measurement and Smallest Detectable Change.
Results: 101 patients suffering from musculoskeletal pain participated in the study. No floor nor ceiling effects were observed.
A Cronbach’s alpha of 0.65 was found, revealing moderate internal consistency. All items were demonstrated to be significantly
correlated with the total score (range of correlations: r=0.2 for item 7 to r=0.78 for item 1). A significant correlation of r=0.78
between the French Keele STarT MSK Tool and the ÖMPSQ-short was found. Nevertheless, a poor agreement between tools
was found, highlighted by a Kappa value of 0.57. Test-retest reliability was excellent (Intraclass Correlation Coefficient 0.97).
The Standard Error of Measurement and Smallest Detectable Change of ±1.17 were 0.42 and ±1.17, respectively. Conclusion:
A validated French version of the Keele STarT MSK Tool is now available and can be used by health practitioners to stratify
patients as being low, medium or high risk for persistent musculoskeletal pain.
KEYWORDS: Chronic pain, Musculoskeletal pain, Translation, Validation Study.
Introduction
Musculoskeletal (MSK) conditions represent a considerable problem
worldwide [1, 2]. MSK pain is prevalent and can place a heavy burden for
those aected [3]. Moreover, consultations rates for MSK pain account
for around a fifth of all consultations in primary care [4]. MSK conditions
therefore have a major impact, not only for the individual but also on the
health care system and society.
Patients with MSK pain in dierent body regions share common prog-
nostic factors, as highlighted in a recent systematic review [5]. Therefore,
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prognostic stratification with recommended matched treatments for each
subgroup has been suggested as clinically relevant and cost-eective. The
Start Back Screening Tool (SBST), developed and validated in 2008 by
Hill et al. [6, 7], is a brief questionnaire designed to screen primary care
patients with low back pain for prognostic indicators that are relevant to
initial decision making. This tool became rapidly very popular. Indeed,
with a simple tool, patients are matched to treatment packages appro-
priate for them, which significantly decrease disability from low back
pain, reduce time o work and save money by making better use of health
resources.
Recently, a modified, generic version of the SBST, has been developed
by Campbell et al. [8] for other musculoskeletal conditions. This new
tool, the Keele STarT MSK Tool, allows for the stratification of primary
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care patients suering from one of the five most common types of mus-
culoskeletal pain (back, neck, shoulder and multi-site pain) into three
sub-groups at risk of chronic pain (low-, medium-and high risk). This tool
has been designed to assist clinicians in their clinical decision making,
by giving information on the likely risk of a poor outcome at the time
a patient consults [9, 10]. The Keele STarT MSK Tool is comprised of
10 items assessing individual’s function and disability, pain and coping,
comorbidity and the impact of pain. The first item is composed of a 0-10
numeric rating scale (NRS) for pain and the remaining nine items consist
of yes/no questions. The total score of the Keele STarT MSK Tool ranges
therefore from 0 to 12 points. Participants with a score between 0 and 4
points, 5 and 8 points or 9 and 12 points are respectively considered at
low, moderate or high risk of chronic pain [11].
The Keele STarT MSK Tool has shown good predictive and discriminative
ability in development and validation samples [11, 12]. The Keele STarT
MSK Tool was initially developed in English and, to our knowledge, has
only been translated into Dutch [13]. Despite French being one of the
most widespread languages worldwide and the fifth most spoken lan-
guage, no French version of the Keele STarT MSK Tool is available. The
objective of this study was therefore to translate the Keele STarT MSK
Tool into French and to investigate its psychometric properties so as to
confirm its validity and reliability as an instrument to classify risk of
chronic pain for primary care patients suering from MSK pain.
Methods
The study was developed using two main steps. First, the Keele STarT
MSK Tool was translated in French and culturally adapted. Then, the
questionnaire was submitted to a sample of individuals suering from
musculoskeletal pain for measuring psychometric properties of the
French Keele STarT MSK Tool, respectively its internal consistency,
test-retest reliability, construct validity and floor/ceiling eects. The
study of the psychometric properties was performed considering the
principles of the Consensus-based Standards for the Selection of Health
Status Measurement Instruments (COSMIN) recommendations [14].The
full protocol of the study is available under request to the corresponding
author. The study protocol was approved by the Ethical Committee of
the University of Liège.
French Translation and Adaptation Process
Permission was obtained from the developers of the Keele STarT MSK
Tool to translate the questionnaire. The translation of the Keele STarT
MSK Tool from English to French was performed according to guidelines
of Guillemin et al.[15] and Beaton et al.[16]. This translation consisted
of 6 phases: 1) during the first phase, the “forward-translation”, two
bilingual translators, native French-speakers, independently translated
the tool into French; 2) during the second phase, a consensual version
was produced by the two native French speakers; 3) during the third
phase, the “back translation”, two bilingual translators, native English-
speakers, independently translated the common version back into English
to check its accuracy; 4) during the fourth phase, an expert committee,
composed of the four translators and a moderator, reviewed all of the
documents, evaluated the conceptual dierences between the original
questionnaire and the back-translated version and produced a first version
of the translated tool; 5) during the fifth phase the translated Keele STarT
MSK Tool was subsequently presented to a linguist, to make sure that the
translation was appropriate; 6) finally, during the last phase, the tool was
submitted to 30 participants for a pre-test.
Study population
Candidates were eligible if they were adults and if they had recently
consulted a doctor (either their general practitioner or their specialist)
for knee, cervical, scapular or diuse musculoskeletal pain. Individuals
suering from cancer, inflammatory arthritis, spondylarthritis, neuro-
logical disease or individuals with recent trauma, cognitive impairment,
dementia, terminal illness or suering from pain related to pregnancy
were excluded. Participants were recruited at the University Hospital
of Liège (Belgium), at the Mont-Falise Hospital (Belgium) and also by
means of social media and flyers distributed in gyms, physical therapy
practices and companies/industries. Individual consent to participate
was obtained from participants.
At the beginning of the study, socio-demographics characteristics as well
as the site of pain of participants were recorded. Once included, partici-
pants were asked to complete the French Keele STarT MSK Tool twice,
with a 7-day interval between. They were also invited to complete two
additional questionnaires. First, they completed the French validated
version of the Örebro Musculoskeletal Pain Screening Questionnaire
Short-Form (ÖMPSQ-short) [17, 18], which is a 10-item questionnaire
that identifies workers at a higher risk of work disability. The total score
obtained varies from 1 to 100 points, with a score higher than 50 reflect-
ing a higher estimated risk for future work disability [19]. Second, they
completed the French version of the Short-Form 12 (SF-12) questionnaire
[20], which is a generic quality of life questionnaire. The SF-12 contains
a mental component (MCS) and a physical component (PCS) both are
scored out of 100 points.
Participants were categorized as being at low, moderate or high risk of
chronic MSK pain according to the results of the French Keele STarT
MSK Tool. Dierences of sociodemographic and clinical characteristics
between these three categories were measured using an ANOVA for con-
tinuous variables that followed a normal distribution, a Kruskal-Wallis
test for continuous variables that did not follow a normal distribution
and with a Chi squared test or Fisher exact test for qualitative variables.
Psychometric evaluations
All analyses were carried out with IBM SPSS for Windows, version 25
(Armonk, NY: IBM Corp.). Normality of distribution of continuous
variables was first established on the basis of the distance between mean
and median, the histogram, the quantile-quantile plot and the Shapiro-
Wilk test. Variables that displayed normal distribution were reported
as mean and standard deviation, and non-normal variables as median
and interquartile range (P25–P75). Qualitative and binary variables were
expressed as absolute and relative frequencies. Moreover, the choice of
psychometric statistics used in the analyses was made according to the
distribution of variables.
Internal consistency: The estimation of homogeneity across items of
the French Keele STarT MSK Tool, or internal consistency, was anal-
ysed by calculating the Cronbach’s alpha of the total score. The value of
alpha varies between 0 and 1, with a good level of internal consistency
established when the alpha value ranges from 0.70 to 0.95 [21].The ques-
tionnaire’s internal consistency was evaluated as a whole and by deleting
a single item one by one. Moreover, to further test internal consistency,
we also measured correlations between the total score and each individual
item. Significant correlations higher than 0.6 were considered as strong
correlations [22].
Construct validity: The construct validity of the French Keele STarT
MSK Tool was analysed by correlation with the ÖMPSQ-short. Pearson’s
correlation coecient was used for comparison with a high correlation
expected between both instruments. Significant correlations higher than
0.6 were considered as strong corelations [22]. Moreover, a Cohen Kappa
Coecient was measured to reflect agreement between the Keele STarT
MSK Tool and the ÖMPSQ-short for the categorization of patients at
high risk of chronic pain. A Cohen Kappa coecient higher than 0.6 was
considered as acceptable [23].
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Floor/ceiling effects: Floor and ceiling eects were considered to be
present if more than 15% of the population obtained a maximum score
(ceiling eect) or a minimum score (floor eect).
Test-retest reliability: Test-retest reliability shows the extent to which
the questionnaire produces the same scores for repeated measurements
in participants whose health has not changed [24]. For the one-week
test-retest reliability, the Intraclass Correlation Coecient (ICC – two-
way mixed, absolute agreement) was calculated for the total score of the
questionnaire. ICC values higher than 0.7 were considered as acceptable
[25]. Cohen’s Kappa coecient was calculated for individual binary items,
with values higher than 0.6 considered as acceptable [23]. The standard
error of measurement (SEM) and the smallest detectable change (SDC)
of the questionnaire were also calculated using the following formulas
[21]: SEM= SD * square root (1-ICC) SDC= 1.96 * SEM * square root
(2) The SEM provides a range around the observed value in which the
theoretical “true” value lies. The SDC indicates the amount of change
that needs to be measured to be sure that the change measured is real,
and not potentially a product of measurement error [24].
Results
French Translation and Adaptation Process
The 10 questions of the Keele STarT MSK Tool were translated without
any major diculties. All dierences between translators, both in the
phases of translation and back-translation, were resolved by consensus. A
prefinal version of the translated questionnaire was pre-tested with 30
participants. The comprehensibility of the questionnaire was excellent,
no further change was required during this pilot phase. The final French
version of the tool has been validated by the expert committee and is
available in Appendix 1.
Psychometric evaluation
Study population: 101 participants took part in this study and com-
pleted both the French Keele STarT MSK Tool and the ÖMPSQ-short
tools. The sample consisted of 63 women and 38 men with a median
age of 25.0 years (interquartile range 21.5-41.0 years). The majority of
the sample was composed of active workers (44.6%) or students (34.7%).
Respectively 29, 54 and 18 participants were categorized as low, moderate
and high risk of chronic pain according to the Keele STarT MSK Tool.
Back pain was the most frequently reported symptom by the participants
(26.7% of the sample), followed by knee pain (24.8% of the sample). Based
on the first item of the Keele STarT MSK Tool, pain was significantly
lower for individuals categorized as low risk of chronic pain (p<0.001).
Moreover, a better quality of life, both for the mental (p=0.01) and physi-
cal component scales (p<0.001) of the SF-12 was observed for individuals
at low risk of chronic pain (Table 1).
Internal consistency: A Cronbach’s alpha of 0.65 was found revealing
moderate internal consistency. When one item was removed from the
analysis, the lowest Cronbach’s alpha obtained was 0.55 (when removing
item 1). Removing other items did not aect the internal consistency of
the French Keele STarT MSK Tool (Table 2). All items also demonstrated
significant correlations with the total score (highest correlation for item
1 with r=0.78, p<0.001, lowest correlation for item 7 with r=0.2, p=0.04).
Construct validity: The French Keele STarT MSK Tool had good con-
struct validity highlighted by a strong and significant correlation with
the ÖMPSQ-short (r=0.78, p<0.001). The ÖMPSQ-short score was signif-
icantly lower for participants at low risk of chronic pain, as diagnosed
with the Keele STarT MSK Tool (28 ± 10.8 points vs 42.1 ± 11.5 points vs
65 ± 11.9 points for individuals at low, moderate and high risk of chronic
pain, p<0.001, respectively) (Table 1). Using the Keele STarT MSK Tool,
18 (18%) of the participants were categorized as “high risk”, using the
ÖMPSQ-short, 30 (30%) were categorized as “high risk”. Agreement be-
tween both tools was not optimal, however, with a kappa coecient of
0.57, (95% CI 0.39 ; 0.75, p<0.001).
Floor and Ceiling effects: No floor, nor ceiling eect was observed
for the French Keele STarT MSK Tool.
Test-retest reliability Among the 101 participants, 51 participants did
not report any modification of pain during the 7-day interval and could
therefore be invited to complete the French Keele STarT MSK Tool
a second time. Test-retest reliability for those 51 participants for the
total score was excellent with an ICC of 0.97 (95% CI 0.95-0.98). Kappa
Coecient values for individual items were excellent and ranged from
0.79-0.95 (Table 3). Using this sample of 51 participants included in
reliability analyses, a SEM of 0.42 and a SDC of 1.17 were obtained.
Discussion
Evidence shows that chronic MSK pain represents a considerable burden
for the individual and society. It is essential to have tools to categorize
individuals into subgroups to oer matched and appropriate treatments
with regards to the clinical conditions of patients and avoid pain becom-
ing chronific. Our study has established a French version of the Keele
STarT MSK Tool with acceptable internal consistency, excellent test-
retest reliability and absence of floor/ceiling eects. Although we found
a good correlation between the total scores of the French Keele STarT
MSK Tool and the French ÖMPSQ-short tool, there was poor agreement
between both tools in identifying patients at high risk of chronic pain,
highlighted by a Kappa coecient of 0.57.
To provide equivalence between the English and the new French version
of the Keele STarT MSK Tool, a rigorous translation and cross-cultural
adaptation process was followed. Input from the 30 participants of the
pre-test and from a linguistic expert during the expert committee review
confirmed that the French Keele STarT MSK Tool has the same content
as the original English Keele STarT MSK Tool, while also being compre-
hensible to its target audience.
The sample of participants included in the validity study consisted of
101 individuals suering from one of the five most common types of
musculoskeletal pain. In accordance with the literature, highlighting a
higher proportion of women in medical consultations for MSK pain [26],
we also included a higher proportion of women in the study (62.4%). In
our sample, the Keele STarT MSK Tool classified 18% of the population
as high risk for chronic pain, which is in between the prevalence found
in the study by Dunn et al. [11] who validated the original Keele STarT
MSK Tool (i.e. 33% of the population was categorized as “high risk”)
and the prevalence found in the study of van den Broek13 et al. who
validated the Dutch translation of the Keele STarT MSK Tool (i.e. 2.8%
of the population was categorized “high risk”). In the Dutch validation
study13, authors raised some hypotheses to explain the low prevalence
found. Among the hypotheses, they explained that they included only
patients that consulted their physiotherapist and not their general prac-
titioners, in contrast with the Dunn et al. [11] study. In our study, we
included participants consulting their general practitioners or addressed
to a physiotherapist by a specialist physician which might explain that
our prevalence was higher than in Van den Broek et al. 13 study.
Psychometric analyses revealed that the French Keele STarT MSK Tool
has a moderate but acceptable internal consistency (Cronbach’s alpha of
0.65). With this value, the internal consistency of the Keele STarT MSK
Tool could not be considerate as excellent. However, all items appear to
be significantly and positively correlated with the total score of the ques-
tionnaire, revealing that, even if homogeneity of the tool is not perfect, it
is nevertheless acceptable for its purpose. Only item 7 demonstrated a rel-
atively low correlation with the total score. Neither the validation of the
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Table 1 Socio-demographic and clinical characteristics of the population
Total sample Low KSMT Moderate KSMT High KSMT p-values*
n=101 (0-4 points) n=29 (5-8 points) n=54 (9-12 points) n=18
Sex
Women 63 (62.4) 15 (51.7) 37 (68.5) 11 (61.1) 0.32
Age (years) 25.0 (21.5-41.0) 24.5 (21.0-27.1) 27.0 (22.7-41.7) 24.5 (20.7-41.2) 0.29
Professional status
Active 45 (44.6) 9 (31.0) 28 (51.9) 8 (44.4) 0.48
Student 35 (34.7) 12 (41.4) 16 (29.6) 7 (38.9)
Incapacity 8 (7.9) 2 (6.8) 4 (7.4) 2 (11.1)
Retired 6 (5.9) 2 (6.9) 3 (5.6) 1 (5.6)
Unemployed 7 (6.9) 4 (13.8) 3 (5.6) 0 (0.0)
BMI (kg/m²) 24.1 (20.9-26.4) 24.5 (21.0-27.1) 24.0 (20.7-26.2) 23.9 (20.6-27.1) 0.95
Site of pain
Neck 15 (14.9) 4 (13.8) 8 (14.8) 3 (16.7) 0.14
Back 27 (26.7) 6 (20.7) 16 (29.6) 5 (27.8)
Shoulder 18 (17.8) 5 (17.2) 12 (22.2) 1 (5.6)
Knee 25 (24.8) 12 (41.4) 10 (18.5) 3 (16.7)
Multi-site 16 (15.8) 2 (6.9) 8 (14.8) 6 (33.3)
Pain (NRS) 5.64 ± 2.05 3.59 ± 1.35 5.96 ± 1.47 8.00 ± 1.24 <0.001
SF-12
PCS (/100) 50.0 ± 9.52 56.5 ± 7.52 50.0 ± 7.55 39.4 ± 8.44 <0.001
MCS (/100) 50.0 ± 10.3 51.1 ± 10.9 51.3 ± 9.94 44.2 ± 9.03 0.01
ÖMPSQ-short 42.1 ± 16.7 28.0 ± 10.8 42.1 ± 11.5 65.0 ± 11.9 <0.001
KSMT (0/12) 5.74 ± 2.56 2.6 ± 1.18 6.2 ± 0.99 9.5 ± 0.71 <0.001
KSMT: Keele STarT MSK tool ; BMI: Body Mass Index ; ÖMPSQ-short: Örebro Musculoskeletal Pain Screening Questionnaire Short-Form; NRS: Numeric
Rating Scale *p-values for continuous variables obtained from an ANOVA test for continuous variables with a normal distribution (ÖMPSQ-short,
Pain(NRS), SF-12 and KSMT) and from a Kruskal-Wallis test for continuous variables without a normal distribution (age and BMI) ; p-values for
qualitative variables obtained from a Chi² test or a Fisher exact test.
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Table 2 Values of internal consistency
Cronbach’s alpha Correlation with the total P-value for
when item removed score of the KSMT correlation
Item 1 0.55 0.79 <0.001
Item 2 0.61 0.53 <0.001
Item 3 0.61 0.54 <0.001
Item 4 0.66 0.28 0.005
Item 5 0.63 0.44 <0.001
Item 6 0.62 0.47 <0.001
Item 7 0.66 0.20 0.04
Item 8 0.58 0.64 <0.001
Item 9 0.63 0.44 <0.001
Item 10 0.63 0.44 <0.001
KSMT: Keele STarT MSK tool
Table 3 Kappa Coecient values for each individual items
Item Kappa 95%CI
Item 1 0.81 0.70 ; 0.94
Item 2 0.89 0.74 ; 1.04
Item 3 0.95 0.85 ; 1.05
Item 4 0.89 0.74 ; 1.04
Item 5 0.79 0.56 ;1.01
Item 6 0.95 0.84 ; 1.05
Item 7 0.93 0.81 ; 1.06
Item 8 0.91 0.79 ; 1.03
Item 9 0.91 0.78 ; 1.03
Item 10 0.95 0.86 ; 1.04
original tool [11] nor the validation of the Dutch translation of the Keele
STarT MSK Tool13, provided a measure of internal consistency of the
tool, which prevents us from comparison. During the French translation
and validation of the SBST, the authors found a Cronbach’s alpha of 0.74
for the psychological subscale of the tool, which is close, but nevertheless
better than the internal reliability of the Keele STarT MSK Tool. How-
ever, the Keele STarT MSK Tool does not have a psychological subscale,
which does not allow for optimal comparison between the tools.
Construct validity of the French Keele STarT MSK Tool has been demon-
strated by a strong, positive and significant correlation with the ÖMPSQ-
short questionnaire [27]. Nevertheless, when measuring agreement be-
tween tools to classify individuals as “high risk” of chronic pain, we found
poor concordance, with a Kappa coecient of 0.57, which is below the ac-
ceptable threshold of 0.6. This apparently opposite result simply reflects
that both tools seem to evolve in the same direction and are therefore
correlated but, unfortunately, they do not classify the same individuals as
high risk.
We also demonstrated excellent test-retest reliability over a one-week
period, both for individual items and for the total score of the French
Keele STarT MSK Tool. For this analysis, only half of the participants
completed the French Keele STarT MSK Tool twice. Even if the sample
was restricted compared to the full sample of participants, the sample
size is acceptable from a methodological point of view16. The validation
of the original Keele StarT MSK tool did not provide a reliability analysis.
However, in the Dutch translation and validation study, authors found a
quadratic-weighted kappa coecient for the total score of 0.71. Because of
the continuous format of the total score of the questionnaire, we decided
to measure an ICC for the total score and measure Kappa Coecients for
all items separately. We found high values of reliability with an ICC of
0.97 for the total score and Kappa values higher than 0.79 for individual
items, which confirmed high reliability of the questionnaire. In our study,
we were also able to calculate the standard error of measurement and
minimal detectable change of the questionnaire, which was not computed
in prior studies. The MDC for the French Keele STarT MSK Tool is 1.17
points (on a scale from 0 to 12 points), which means that a individuals
would have to change by at least this amount before we can be sure that
he/she has actually improved or deteriorated.
Finally, no floor nor ceiling eects were identified. This psychometric
property is important for the capacity of the tool to detect changes. When
floor/ceiling eects are identified, tools are less sensitive to change and
less able to discriminate between patients.
Limitations
Because of the cross-sectional design of our study, we were unable measure
the responsiveness, the minimal clinical important dierence nor the
predictive validity of the French Keele STarT MSK Tool. During their
Dutch translation process, van de Broek et al.13 measured the ability of
the Dutch Keele STarT MSK Tool to predict persisting disability at 3
months. They found relative risk ratios for persisting disability of 2.2 for
the medium risk group and 7.3 for the high-risk group. However, even if
they were the first ones to provide longitudinal psychometric properties
of this questionnaire, their sample size for high-risk patients only included
4 patients, which limits generalisability of findings in this group. Still
because of the cross-sectional design of the study, we measured the validity
of the French Keele STarT MSK tool only through construct validity and
not using criterion validity, which is also questionable. Indeed, it would
have been very informative to obtain longitudinal data on the incidence
of chronic pain in our population and the possible association between
this incidence and the results obtained from the Keele STarT MSK tool.
Another possible limitation of our study is that almost 80% of our sample
was comprised of active workers and students. A selection bias may have
occurred because we mainly recruited via social networks and flyers in
companies/industries. Therefore, our sample is represented by a high
proportion of active workers, and a lower proportion of unemployed or
retired participants, or people with work incapacities.
Perspective
Results of our study encourages clinicians to use the French Keele STarT
MSK tool to help identify French-speaking patients at risk of chronic-
ity and to identify the presence of psychosocial factors to be taken into
account in the clinical management of the patient. Because the respon-
siveness, the minimal clinical important dierence, and the criterion
validity of the questionnaire have never been measured, further longitu-
dinal studies using the Keele STarT MSK tool should be encouraged.
Conclusion
The French version of the Keele STarT MSK Tool is now available and
shows good validity and reliability values. This tool can be used with
confidence to obtain a classification of individuals suering from MSK
conditions at low, moderate or high risk of chronic pain. Before this
study, the Keele STarT MSK Tool had been only validated in one unique
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population study. With this study, we validated it in a second cohort from
a dierent country.
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